Cingulate Inc (CING) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cingulate Inc (CING) has a cash flow conversion efficiency ratio of -1.434x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.60 Million) by net assets ($2.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cingulate Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Cingulate Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Cingulate Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cingulate Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cingulate Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Norcod As
OL:NCOD
|
-0.333x |
|
Campina Ice Cream Industry Tbk PT
JK:CAMP
|
0.086x |
|
Ways Technical Ltd
TWO:3508
|
-0.047x |
|
Maat Pharma SA
PA:MAAT
|
-1.853x |
|
Falcon Machine Tools Co Ltd
TWO:4513
|
-0.035x |
|
Dongyang Expre
KO:084670
|
0.059x |
|
Oriental Food Industries Hold
KLSE:7107
|
0.047x |
|
Herige SA
PA:ALHRG
|
0.119x |
Annual Cash Flow Conversion Efficiency for Cingulate Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cingulate Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Cingulate Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.51 Million | $-17.25 Million | -6.874x | -177.73% |
| 2024-12-31 | $7.46 Million | $-18.45 Million | -2.475x | -213.08% |
| 2023-12-31 | $-6.87 Million | $-15.03 Million | 2.189x | +153.49% |
| 2022-12-31 | $3.88 Million | $-15.88 Million | -4.091x | -717.41% |
| 2021-12-31 | $20.84 Million | $-10.43 Million | -0.501x | +90.50% |
| 2020-12-31 | $1.29 Million | $-6.81 Million | -5.270x | +65.95% |
| 2019-12-31 | $615.88K | $-9.53 Million | -15.478x | -- |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more